21.57 USD
↘ 1.51 (6.54%)LIVE (AS OF 02:23 PM EDT)
Tango Therapeutics, Inc.
TNGXNASDAQ • USD
Market: OPEN
TNGX is currently priced at $21.57. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, TNGX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Oct 5, 2026.
Open?$23.16
High?$23.40
Low?$21.37
Prev. Close?$23.08
Volume?2.9M
Avg. Volume?2.9M
VWAP?$21.93
Rel. Volume?1.01x
Bid / Ask
Bid?$21.55 × 100
Ask?$21.60 × 100
Spread?$0.05
Midpoint?$21.58
Valuation & Ratios
Market Cap?3.9B
Shares Out?168.6M
Float?140.4M
Float %?83.3%
P/E Ratio?N/A
P/B Ratio?3.80
EPS?-$0.73
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Address
201 BROOKLINE AVENUE
BOSTON, MA 02215
Phone: (857) 320-4900
BOSTON, MA 02215
Phone: (857) 320-4900
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?10
Piotroski F-Score?0/9Weak
Altman Z-Score?47.16Safe
Confidence?52%Low
Short InterestSqueeze Risk
Short % of Float?29.82%Squeeze Risk
Short Interest?41.9M
Days to Cover?18.8
Free Float140.4M
Avg Daily Volume2.2M
Settlement Date2026-09-15
Financial Health
Current Ratio?50.82Strong
Quick Ratio?50.82Strong
Cash Ratio?17.02Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.80FAIR▾
Peers100
S&P46
P/S?72.32HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-26.4CHEAP▾
S&P97
EV/Sales?65.90HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-12.1%WEAK▾
S&P9
ROA?-11.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-144247000
Enterprise Value?$3.5B
Fundamentals ratios updated end of day